VALLEY FORGE, Pa.--(BUSINESS WIRE)--Xcenda, a part of AmerisourceBergen, today announced the acquisition of Dymaxium, a trusted market access partner specializing in the exchange of evidence and information between payers and life science companies through its FormularyDecisions.com® platform. This acquisition will further simplify and streamline the necessary communication of clinical evidence and health economic information between manufacturers and population health decision makers.
Over the past decade, Dymaxium built FormularyDecisions.com for payers to provide them efficient access to clinical evidence and economic product information critical to their assessment of products for formulary evaluations. Information is provided by subscribing manufacturers and amassed across multiple independent third-party data sources. Payers use this information along with other platform tools to assess value throughout a product’s lifecycle (pre-, peri- and post-approval) and to aid in evidence-based reimbursement decision making. The FormularyDecisions.com platform, home to the AMCP (Academy of Managed Care Pharmacy) eDossier System, allows for the bi-directional exchange of information, more frequently and effectively, through ongoing feedback channels for insights on the information most valuable to payer decision makers.
“Xcenda was founded on the principle of generating credible and practical health economics and outcomes research for stakeholders to make informed healthcare decisions that consider the clinical, economic, and humanistic outcomes of a product,” said Dr. Kristine Flemister, President of Xcenda. “We are constantly searching for innovative offerings that make this exchange of information between pharma and payers simpler and more efficient. We are thrilled to make this a reality through this acquisition with Dymaxium’s FormularyDecisions.com and the AMCP eDossier System.”
“With over 2100 registered US payers and healthcare decision makers and 2,300+ FDA approved plus 225+ pre-approval products, Dymaxium’s platform uniquely supports the exchange of information between payers and life science organizations to drive value-based reimbursement decisions,” said Allen Lising, Managing Director of Dymaxium. “We are excited about combining our technology platform offerings and US payer community with Xcenda’s leading global market access and health economics expertise. This partnership accelerates the delivery of our vision to make early and ongoing exchange of credible product value information between payers and manufacturers a reality. We look forward to being able to deliver more information on pipeline and approved products to payers and providing actionable insights to manufacturers on the information and value needs of payers.”
More information on the Dymaxium and FormularyDecisions.com acquisition will be available at the ISPOR Annual Meeting, taking place in New Orleans, LA from May 19-22, 2019.
AmerisourceBergen provides pharmaceutical products, value-driving services and business solutions that improve access to care. Tens of thousands of healthcare providers, veterinary practices and livestock producers trust us as their partner in the pharmaceutical supply chain. Global manufacturers depend on us for services that drive commercial success for their products. Through our daily work—and powered by our 21,000 associates—we are united in our responsibility to create healthier futures. AmerisourceBergen is ranked #12 on the Fortune 500, with more than $160 billion in annual revenue. The company is headquartered in Valley Forge, Pa. and has a presence in 50+ countries. Learn more at amerisourcebergen.com.
For more than 2 decades, companies have turned to Xcenda’s leading team of value experts, transforming evidence and market intelligence into effective global market access strategies and solutions. Founded in the application of health outcomes and reimbursement, it’s our goal to help prove the inherent worth of client products and services, maximize patient access, and enhance overall brand performance. (http://xcenda.com)
Dymaxium (http://www.dymaxium.com) has specialized in the exchange of evidence and information between decision makers and life sciences organizations since 1996. By leveraging their FormularyDecisions.com® platform and its 2100+ registered US payers and health care decision makers, Dymaxium created the unique opportunity for insights about reimbursement decisions: ongoing feedback from active decision makers via syndicated payer feedback, payer behavior metrics and new interactive dashboard reporting. Subscribing life sciences organizations access these syndicated insights and data to support effective product information exchange with decision makers during pre- and post-approval.